Author Archives

FREDERICK, MD–(Marketwired – Nov 6, 2017) – BioElectronics Corporation ( OTC PINK :BIEL ), the maker of advanced consumer pain management medical device, ActiPatch, today announced that it has taken on the responsibility to find a DRUG-FREE solution to the Opioid Crisis. The reach of the opioid crisis now stretches wide and far, claiming an American life every … Continue Reading

FREDERICK, MD–(Marketwired – Oct 16, 2017) – BioElectronics Corporation ( OTC PINK : BIEL ), www.bielcorp.com is pleased to announce the commencement of a clinical study investigating the efficacy of ActiPatch in treating chronic musculoskeletal lower back pain. Low back pain is highly prevalent and affects 1 in 3 adult Americans, accounting for about $ 90 billion in direct spending every … Continue Reading

FREDERICK, MD–(Marketwired – Sep 25, 2017) –  BioElectronics Corporation ( OTC PINK : BIEL ), www.bielcorp.com is pleased to report on the progress of its Migraine prevention clinical study. The randomized, double-blinded, sham-controlled study involving 48 subjects is designed to investigate if ActiPatch therapy can be used to prevent the frequency and intensity of migraine attacks. Since receiving IRB-approval for the … Continue Reading

FREDERICK, MD–(Marketwired – Aug 28, 2017) – The following is a statement from BioElectronics ( OTC PINK : BIEL ). Dear Fellow Shareholders, These are busy and exciting times at BioElectronics ( OTC PINK : BIEL ). New Product Opportunities Over the last few years, there have been two significant developments: 1) There has been a paradigm shift in the medical community’s understanding of how … Continue Reading

FREDERICK, MD–(Marketwired – Aug 22, 2017) – The following is a statement from BioElectronics ( OTC PINK : BIEL ). Dear Fellow Shareholders, These are busy and exciting times at BioElectronics. New Product Opportunities Over the last few years, there have been two significant developments: 1) There has been a paradigm shift in the medical community’s understanding of how … Continue Reading

FREDERICK, MD–(Marketwired – Aug 22, 2017) –  BioElectronics Corporation ( OTC PINK : BIEL ), the maker of advanced consumer pain management medical devices, today announced that it has engaged Keith Nalepka as the Vice President of Sales and Marketing. Keith has over 15 years of experience working in the retail sales industry, both with large multi-million dollar brands … Continue Reading

FREDERICK, MD–(Marketwired – Aug 8, 2017) – BioElectronics Corporation ( OTC PINK :BIEL ), www.bielcorp.com is pleased to report on the progress of its Migraine prevention clinical study. The randomized, double-blinded, sham-controlled study involving 48 subjects is designed to investigate if ActiPatch therapy can be used to prevent the frequency and intensity of migraine attacks. Since receiving IRB-approval for the … Continue Reading

FREDERICK, MD–(Marketwired – Aug 2, 2017) –  ( OTC PINK : BIEL ) BioElectronics Corporation’s ActiPatch®, The New Technology for Pain Relief medical device, has won the Orthopedics This Week Sports Medicine Technology Award. Orthopedics This Week is the most widely read publication by clinicians, nurses, scientists, and others in the orthopedics industry. The panel of judges consisted of experienced orthopedic sports medicine … Continue Reading

FREDERICK, MD–(Marketwired – Jun 30, 2017) –  BioElectronics Corporation ( OTC PINK : BIEL ) www.bielcorp.com, is pleased to announce that Sree Koneru, Ph. D., VP of Product Development, will speak about the new science and technology behind chronic pain relief at the 2017 UK Pharmacy Forward Annual Conference. This meeting brings together independent and small-chain pharmacists for a one-day … Continue Reading

FREDERICK, MD–(Marketwired – Jun 29, 2017) –  BioElectronics Corporation ( OTC PINK : BIEL ), www.bielcorp.com is pleased to announce the completion of a health economics study using its nonprescription drug-free ActiPatch® Musculoskeletal Pain Therapy for chronic pain. The goal was to investigate how using ActiPatch as a pain therapy would affect overall healthcare costs in the UK. The study involved … Continue Reading